Concepedia

Author

Pablo Mozas

Consorci Institut D'Investigacions Biomediques August Pi I SunyerORCID

Also Known As

Mozas, Pablo, P. Mozas, Pablo Mozas

106

Publications

706

Citations

13

H-Index

23

Concepts

All Affiliations

Consorci Institut D'Investigacions Biomediques August Pi I SunyerCentro de Investigación Biomédica en Red de CáncerHospital Clínic de BarcelonaUniversitat de BarcelonaHospital Del Mar
PM

About

Pablo Mozas is an author at Consorci Institut D'Investigacions Biomediques August Pi I Sunyer specializing in medicine, pathology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

55

2

Immunology

4

4

55

3

Pathology

4

4

55

4

Cell Biology

1

1

10

5

Molecular Medicine

1

1

10

Pablo Mozas

×

17

Publications

515

Citations

13

H-Index

YearCitations

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers ( <scp> <i>IGHV</i> </scp> mutational status and <scp>FISH</scp> cytogenetics) separates patients with different outcome and simplifies the <scp>CLL‐IPI</scp>

Julio Delgado, Michael Doubek, Tycho Baumann,

American Journal of Hematology

2017

93

Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Alfredo Rivas‐Delgado, Ferran Nadeu, Anna Enjuanes,

Clinical Cancer Research

2020

91

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

Alfredo Rivas‐Delgado, Laura Magnano, Miriam Moreno‐Velázquez,

British Journal of Haematology

2018

79

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Álex Bataller, Ana Garrido, Francesca Guijarro,

Blood Advances

2021

54

Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience

Pablo Mozas, Ferran Nadeu, Alfredo Rivas‐Delgado,

Blood Cancer Journal

2020

34

High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era

Pablo Mozas, Alfredo Rivas‐Delgado, Andrea Rivero,

Leukemia Research

2020

18

Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution

Andrea Rivero, Pablo Mozas, Laura Jiménez,

Cancers

2021

18

The academic point‐of‐care <scp>anti‐CD19</scp> chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (<scp>ARI</scp>‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell <scp>non‐Hodgkin</scp> lymphoma

Núria Martínez‐Cibrián, Valentín Ortiz‐Maldonado, Marta Español‐Rego,

British Journal of Haematology

2023

18

Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma

Alfredo Rivas‐Delgado, Ferran Nadeu, Marcio Andrade‐Campos,

Diagnostics

2022

14

Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

Pablo Mozas, Cristina López, Marta Grau,

Hematological Oncology

2023

14

Page 1